CEC - Key Persons
David has more than 40 years' experience in International Banking & Finance, Corporate Advice, IP Licensing and application, renewable energy, wastewater, food production, LHW, private family offices and many other industries. He has been involved in creation, protection and commercialization of IP worldwide for clients and for his own companies.
David incorporated the Clean Energy Capital Group in Australia in 2008 and in Singapore in 2018 (previously named Advancing World Partners). Prior to incorporating CEC David owned a Group that developed, registered and commercially exploited IP worldwide in various Industries including renewable energy, steel, food and chemicals.
Previously he was the Melbourne representative of a Sydney based Corporate Advisor that delivered services to large private groups in the medical, health care, real estate golf resort industries and for 12 years worked for the First National Bank of Chicago in Melbourne and Sydney.
David holds a primary Accounting Degree from RMIT University in Melbourne and Master of Commerce for the University of NSW, Australia.
Rob trained as a scientist, in molecular and cell biology, and genetics, obtaining his PhD at Edinburgh University. He spent time at University College London and the Institute of Neurology researching signal transduction in cell development, discovering novel pathways involved in neural development and cancer.
He worked for GSK in the area of preclinical target development, and has published over 40 scientific papers and book chapters, as well as presenting seminars at numerous international conferences.
He worked in Guy's Hospital developing cutting-edge cellular and genetic prenatal diagnostic methods.
Rob was also a senior scientist at the Institute of Molecular and Cell Biology in Singapore. He helped develop several incubation and spin-off companies in the UK as well as in Singapore, and obtained an MBA at Imperial College. While in Singapore he was a founding member of Exploit Technologies and the Industry Development Group of A*STAR (Agency for Science, Technology and Research) and helped build the business development function at the Genome Institute of Singapore.
More recently he has acted as principal consultant for several biotechnology and diagnostics companies; consulted for investment groups; developed a marketing strategy using big data analysis for the healthcare and pharmaceutical sectors; and consulted for the National University Hospital Singapore on matters of intellectual property, clinical trials and global alliances.
Rob joined CEC in 2018 and became a partner in 2019.
Job Titles:
- Managing Partner
- Managing Partner at ME Pharma Consult
Dr. Michael Entzeroth is Managing Partner at ME Pharma Consult, Davao, Philippines and was until 31 December 2019 Chief Scientific Officer/Chief Operating Officer of Cennerv Pharma (S) Pte Ltd in Singapore, a company focused on the development of novel drugs for the treatment of central nervous diseases.
Dr. Paul is currently Director, Life Sciences Institute at the National University of Singapore.
Paul MacAry received his BSc (Hons) in Molecular Biology from Glasgow University in 1992, his PhD in Immunology from GKT, University of London in 1998 followed by Wellcome Trust postdoctoral fellowship positions in Cambridge University until 2005. Since 2005 he has been an independent investigator in the Department of Microbiology and Immunology at the National University of Singapore (NUS). The multi-disciplinary research in his laboratory covers the entire spectrum of scientific endeavour, from basic research to industrial applications with an emphasis on antibody biology, immune repertoire mapping and protein engineering. Paul was a founding member of the Singaporean Society of Immunologists (SgSI)-Singapore's first international learned society (www.sgsi.org.sg/) and the founding scientist for three biotechnology companies, BSCR LTD founded in Cambridge in 2004, Antibody Cradle LTD founded in Singapore in 2012 and Singapore MABs LTD founded in 2016. Paul is also a founding member and Associate Editor of Nature Vaccines (www.nature.com/npjvaccines/), a member of the Faculty of 1000 (https://f1000.com/) and his research has been featured in covering articles on the BBC, CNN and Reuters.
Geoff is a Partner in CEC and an experienced leader with extensive sales, technical, operational, engineering and general management experience within both large multinational companies and smaller private enterprises. Industrial experience includes steel, specialty chemical, waste treatment, renewable fuels and tourism markets.
He has a proven track record of leading and delivering on projects, managing cross border teams, safety and environmental management, process improvement programs and innovative commercial negotiations.
Prior to CEC, he was Operations and Engineering Manager for The Acqua International Group (2005-2010). During this period, he led the design and construction of, what was at the time, one of the largest biodiesel plants in North America.
From 2002-2005, he developed and applied novel recycling technologies specifically into the steel industry. This included product installations in Europe, Asia, North America and Australia.
Job Titles:
- Non - Executive Director
- Managing Director of Solas Fiduciary Services
Martin is a Non-Executive Director of CEC.
Martin is Managing Director of Solas Fiduciary Services, based in Singapore.
Martin is Managing Director of Solas Fiduciary Services, based in Singapore.
With over 20 years' experience and a qualified accountant (CPA, ACCA), Martin's experience encompasses all aspects of audit, compliance, fiduciary, fund administration and banking services. These include hedge funds, fund of funds and other alternative investment vehicles - including fintech, crypto, private equity, infrastructure and real estate. Martin has held several senior positions in the financial services industry. Prior to Solas, he spearheaded Intertrust Singapore with the mandate to expand its fiduciary services in Asia. He previously headed the alternative Funds Services in Asia for Deutsche Bank, Citi Fund Services (Bermuda), Apex Fund Services (Dubai) and UBS Fund Services (Cayman Islands and Hong Kong).
Martin is licensed as a director with the Cayman Islands Monetary Authority (CIMA), pursuant to the Directors Registration and Licensing Law, 2014.